Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer

Abstract

Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 45 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.

Keywords

recurrent ovarian cancer - progression-free survival - platinum-free interval - ayurveda maintenance treatment - ZINCA-30

Publikationsverlauf

Artikel online veröffentlicht:
02. Februar 2022

• References:

• 1 Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol 2017; 28 (Suppl. 08) viii51 , viii56
• 2 Chuang Y-T, Chang C-L. Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: its possible clinical significance. Taiwan J Obstet Gynecol 2012; 51 (03) 336-341
• 3 Soyama H, Takano M, Miyamoto M. et al. Factors favouring long-term survival following recurrence in ovarian cancer. Mol Clin Oncol 2017; 7 (01) 42-46
• 4 Balachandran P, Govindarajan R. Cancer–an ayurvedic perspective. Pharmacol Res 2005; 51 (01) 19-30
• 5 Doshi GM, Une HD, Shanbhag PP. Rasayans and non-rasayans herbs: future immunodrug - Targets. Pharmacogn Rev 2013; 7 (14) 92-96
• 6 Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review. J Ovarian Res 2019; 12 (01) 103
• 7 Jorge S, Swisher EM, Norquist BM. et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep 2019; 29: 113-117
• 8 Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. J Ovarian Res 2014; 7: 57
• 9 Du Bois A, Floquet A, Kim J. et al. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international intergroup trial (AGO-OVAR16). J Clin Oncol 2013; 31 (Suppl. 18) LBA5503-LBA5503
• 10 Pujade-Lauraine E, Ledermann JA, Selle F. et al; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. [published correction appears in Lancet Oncol. 2017 Sep;18(9):e510] Lancet Oncol 2017; 18 (09) 1274-1284
• 11 Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 2018; 81 (01) 17-38
• 12 Pothuri B, O'Cearbhaill R, Eskander R, Armstrong D. Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Gynecol Oncol 2020; 159 (01) 8-12
• 13 Montemorano L, Lightfoot MD, Bixel K. Role of olaparib as maintenance treatment for ovarian cancer: the evidence to date. OncoTargets Ther 2019; 12: 11497-11506
• 14 DiSilvestro P, Alvarez Secord A. Maintenance treatment of recurrent ovarian cancer: is it ready for prime time?. Cancer Treat Rev 2018; 69: 53-65
• 15 Norquist BM, Harrell MI, Brady MF. et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016; 2 (04) 482-490
• 16 Tomao F, D'Incalci M, Biagioli E, Peccatori FA, Colombo N. Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: myth or reality?. Cancer 2017; 123 (18) 3450-3459
• 17 Jorge S, Swisher EM, Norquist BM. et al. Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. Gynecol Oncol Rep 2019; 29: 113-117
• 18 Vayalil PK, Kuttan G, Kuttan R. Rasayanas: evidence for the concept of prevention of diseases. Am J Chin Med 2002; 30 (01) 155-171
• 19 Umrani RD, Paknikar KM. Jasada bhasma, a zinc-based ayurvedic preparation: contemporary evidence of antidiabetic activity inspires development of a nanomedicine. Evid Based Complement Alternat Med 2015; 2015: 193156
• 20 Chavare A, Chowdari P, Ghosh S. et al. Safety and bioactivity studies of Jasad Bhasma and its in-process intermediate in Swiss mice. J Ethnopharmacol 2017; 197: 73-86
• 21 Pal D, Gurjar VK. (2017) Nanometals in Bhasma: ayurvedic medicine. In: Rai, Ph.D M., Shegokar, Ph.D R., eds. Metal Nanoparticles in Pharma. Springer, Cham. doi-org-443.webvpn.fjmu.edu.cn/10.1007/978-3-319-63790-7_17
• 22 Umrani RD, Paknikar KM. Ayurvedic medicine zinc bhasma: physicochemical evaluation, anti-diabetic activity and safety assessment. J Biomed Nanotechnol 2011; 7 (01) 148-149
• 23 Department of AYUSH, Ministry of Health & Family Welfare. The Ayurvedic Formulary of India, Part I. 2nd ed. The Controller of Publications; New Delhi: 2003: 227 , 239
• 24 Bastow M, Kriedt CL, Baldassare J, Shah M, Klein C. Zinc is a potential therapeutic for chemoresistant ovarian cancer. J Exp Ther Oncol 2011; 9 (03) 175-181
• 25 Department of AYUSH, Ministry of Health & Family Welfare. The Ayurvedic Pharmacopeia of India, Part I, Vol V. The Controller of Publications; New Delhi: 2006: 13-15
• 26 Ramachandran C, Lollett IV, Escalon E, Quirin KW, Melnick SJ. Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO₂ extract in human glioblastoma cells. J Evid Based Complementary Altern Med 2015; 20 (02) 109-119
• 27 Lin YG, Kunnumakkara AB, Nair A. et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-KB pathway. Clinical Cancer Research 13 (11) 3423-3430
• 28 Pandey V. ed. Sahastrayog, Kashaya Prakaran, Chap. 1. Verse 171. CCRAS; New Delhi: 1990: 298
• 29 Savrikar SS, Ravishankar B. Bhaishajya Kalpanaa - the Ayurvedic pharmaceutics - an overview. Afr J Tradit Complement Altern Med 2010; 7 (03) 174-184
• 30 Dongre S, Pande S. Need and approach of pharmaceutical standardization of Kwath Kalpana in present scenario-a critique. Int J Ayurveda Pharma Res 2016; 4 (03) 57-60 . Accessed November 26, 2021 at: https://ijapr.in/index.php/ijapr/article/view/321
• 31 Mishra BR, Katre SP. Raktaja Gulma in correlation with modern science conditions. Journal of Ayurveda and Integrated Medical Sciences 2018; 3 (02) 73-77
• 32 George SK, Rajesh R, Kumar S, Sulekha B, Balaram P. A polyherbal ayurvedic drug–Indukantha Ghritha as an adjuvant to cancer chemotherapy via immunomodulation. Immunobiology 2008; 213 (08) 641-649
• 33 Sruthi CV, Vendamirtham S, Sindhu A. from the proceedings of Insight Ayurveda 2013, Coimbatore. 24th and 25th May 2013. PA02.20. A comparative study on the total phenolic content and antioxidant property of two Ayurvedic formulations–Indukantham gritham and Indukantham kashayam. Anc Sci Life 2013; 32 (Suppl. 02) S65